Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Maintains Hardline Approach In New-Tech Add-On Payment Reviews

This article was originally published in The Gray Sheet

Executive Summary

The Medicare agency raised significant questions about the qualifications for all five device applicants for FY 2017 new-technology add-on payments in its latest hospital inpatient proposed rule.

You may also be interested in...



US Medicare Add-On Payments Granted To NuVasive, Gore

The Medicare hospital inpatient final rule gives new technology add-on payments to just two devices, Ellipse Technologies's Magec spinal bracing and distraction system, and Gore's Excluder iliac branch endoprosthesis. Two other requests were turned down, and another device was not FDA-approved in time.

Drug-Coated Balloons Net Medicare Inpatient Bonus Payments

The positive hospital inpatient reimbursement decision for recently launched Medtronic and CR Bard peripheral artery devices follows prior positive policy rulings in the outpatient setting. Meanwhile, CMS rejected Boston Scientific's new-technology add-on application for the Watchman stroke device, but the agency did establish a pricier payment category for the new procedure.

What Lies Ahead: COVID-19 Vaccination Challenges

The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel